UNLABELLED: Common variable immunodeficiency (CVID) is a heterogeneous primary immunodeficiency associated with an increased risk of malignancy in adulthood, with lymphoma as one of the major causes of death. The aim of this study is to describe those malignancies detected in our cohort of pediatric CVID patients. We reviewed the clinical and laboratory data and the treatments and their outcomes in all pediatric CVID patients from our institution that developed a neoplasia. Four malignancies were diagnosed in three out of 27 pediatric CVID patients. Three malignancies were non-Hodgkin lymphoma (NHL) of B cell origin (mean age at diagnosis: 8 years old), and the remaining was a low-grade astrocytoma. Among NHL, two were mucosa-associated lymphoid tissue (MALT) lymphomas and one was associated with Epstein-Barr virus infection. NHL developed before CVID diagnosis in two patients. CVID patients showed different clinical phenotypes and belonged to different groups according Euroclass and Pediatric classification criteria. CONCLUSIONS: Malignancies, especially lymphoma, may develop in pediatric CVID patients with no previous signs of lymphoid hyperplasia and even before CVID diagnosis. Consequently, strategies for cancer prevention and/or early diagnosis are required in pediatric CVID patients.
UNLABELLED: Common variable immunodeficiency (CVID) is a heterogeneous primary immunodeficiency associated with an increased risk of malignancy in adulthood, with lymphoma as one of the major causes of death. The aim of this study is to describe those malignancies detected in our cohort of pediatric CVIDpatients. We reviewed the clinical and laboratory data and the treatments and their outcomes in all pediatric CVIDpatients from our institution that developed a neoplasia. Four malignancies were diagnosed in three out of 27 pediatric CVIDpatients. Three malignancies were non-Hodgkin lymphoma (NHL) of B cell origin (mean age at diagnosis: 8 years old), and the remaining was a low-grade astrocytoma. Among NHL, two were mucosa-associated lymphoid tissue (MALT) lymphomas and one was associated with Epstein-Barr virus infection. NHL developed before CVID diagnosis in two patients. CVIDpatients showed different clinical phenotypes and belonged to different groups according Euroclass and Pediatric classification criteria. CONCLUSIONS:Malignancies, especially lymphoma, may develop in pediatric CVIDpatients with no previous signs of lymphoid hyperplasia and even before CVID diagnosis. Consequently, strategies for cancer prevention and/or early diagnosis are required in pediatric CVIDpatients.
Authors: M Raeiszadeh; J Kopycinski; S J Paston; T Diss; M Lowdell; G A D Hardy; A D Hislop; S Workman; A Dodi; V Emery; A D Webster Journal: Clin Exp Immunol Date: 2006-11 Impact factor: 4.330
Authors: Helen Chapel; Mary Lucas; Smita Patel; Martin Lee; Charlotte Cunningham-Rundles; Elena Resnick; Laurence Gerard; Eric Oksenhendler Journal: J Allergy Clin Immunol Date: 2012-07-20 Impact factor: 10.793
Authors: P Mohammadinejad; A Aghamohammadi; H Abolhassani; M S Sadaghiani; S Abdollahzade; B Sadeghi; H Soheili; M Tavassoli; S M Fathi; M Tavakol; N Behniafard; B Darabi; S Pourhamdi; N Rezaei Journal: J Investig Allergol Clin Immunol Date: 2012 Impact factor: 4.333
Authors: Paul R Ogershok; Mary Beth Hogan; Jon E Welch; W Thomas Corder; Nevin W Wilson Journal: Ann Allergy Asthma Immunol Date: 2006-11 Impact factor: 6.347
Authors: William H Wheat; Carlyne D Cool; Yoshikazu Morimoto; Pradeep R Rai; Charles H Kirkpatrick; Barbara A Lindenbaum; Christopher A Bates; Misoo C Ellison; Amanda E Serls; Kevin K Brown; John M Routes Journal: J Exp Med Date: 2005-08-15 Impact factor: 14.307
Authors: J Brent; D Guzman; C Bangs; B Grimbacher; C Fayolle; A Huissoon; C Bethune; M Thomas; S Patel; S Jolles; H Alachkar; D Kumaratne; H Baxendale; J D Edgar; M Helbert; S Hambleton; P D Arkwright Journal: Clin Exp Immunol Date: 2016-01-27 Impact factor: 4.330
Authors: Aleksandra Szczawińska-Popłonyk; Katarzyna Ta Polska-Jóźwiak; Eyal Schwartzmann; Natalia Popłonyk Journal: Front Pediatr Date: 2022-03-23 Impact factor: 3.418